OWEGO, NY. – Oct. 31, 2006 – BioLife Solutions Inc. (OTC BB: BLFS), a leading developer and marketer of proprietaryhypothermic storage and freeze media products for cells, tissues, and organs announced the publication of a report that describes the benefits of the combination of the BioLife CryoStor CS5 with Corning’s CellBIND Surface. The integration of these complementary technologies resulted in a significant increase in the survival and attachment of LNCaP cells as compared to traditional solutions and tissue culture treated (TCT) surfaces.

The CryoStor/Corning CellBIND Surface combined approach offers a distinct advantage to the pharmaceutical, drug discovery, and toxicity testing industries by enabling researchers to reduce time and effort presently required to collect, store, retrieve andutilize high-quality cryopreserved cells. This thereby increases productivity and costeffectiveness of in vitro screening processes.

“This validation of CryoStor, our serum-free and protein-free biopreservation medium, provides an important endorsement of our preservation technology platform and intellectual property portfolio,” said Mike Rice, chief executive officer, BioLife Solutions. “The study jointly performed by Corning and BioLife scientists demonstrates fundamental advantages that the combined products offer to a broad industry base, including drug discovery and cellular therapy.”

Data from independent experiments showed that the Cryostor solution and Corning CellBIND surface product combination offered a 58-percent increase in postpreservation cell survival when compared to traditional tissue culture surface and serum and protein based freezing media. It’s important to note cell survival was measured 24 hours post-thaw, a much more relevant performance metric than immediate post-thaw survival measurement, which often gives researchers a false sense about Corning Incorporated.

Corning Incorporated is a diversified technology company that concentrates its efforts on high-impact growth opportunities. Corning combines its expertise in specialty glass, ceramic materials, polymers and the manipulation of the properties of light, with strong process and manufacturing capabilities to develop, engineer and commercialize significant innovative products for the telecommunications, information display, environmental, semiconductor, and life sciences industries.

About BioLife Solutions
BioLife Solutions develops and markets patented hypothermic shipping media and cryopreservation media products for cells, tissues, and organs. The Company’s proprietary HypoThermosol and CryoStor platform of preservation media products are marketed to academic research institutions, clinical care provider organizations, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife’s products are serum-free and protein-free, fully defined, and are formulated to reduce biopreservation-induced, delayed-onset cell damage, and death. BioLife’s enabling technology provides research and clinical organizations significant improvement in post-biopreservation cell and tissue stability, viability, and function. For more information please visitwww.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions’ actual results to differ materially are discussed in the Company’s recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

####